Begin dosing patients in the first antibiotic cohort of the SYN-004 Phase 1b/2a trial
Delivered after the deadline (14 days after the deadline)
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 4 Mar 2021
- Due
- 31 Mar 2021
- Delivered
- 14 Apr 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Expect to begin dosing patients in the first antibiotic cohort of the SYN-004 Phase 1b/2a clinical trial during Q1 2021”
What we found
Evidence strength A What the grades mean
The company announced on April 14, 2021 that the first patient in the first antibiotic cohort had been dosed, after the Q1 2021 deadline. Later filings label the dosing Q2 2021.
-
A Synthetic Biologics, Inc. 10-Q filed 2021-05-05
“On April 14, 2021 we announced that enrollment has commenced and the first patient of the first antibiotic cohort of this study had been dosed.” ✓ confirmed on the page
-
A Synthetic Biologics, Inc. 10-Q filed 2021-08-05
“Washington University began enrollment and the first patient was dosed in the first of three antibiotic cohorts for the Phase 1b/2a clinical trial of SYN-004 in adult HCT recipients (Q2 2021)” ✓ confirmed on the page
-
A Synthetic Biologics, Inc. 10-K filed 2022-03-16
“During the first quarter of 2021, Washington University began enrollment and dosed our first patient in the first of three antibiotic cohorts” ✓ confirmed on the page
Checked 27 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- Dosing of first SYN-004 Phase 1b/2a antibiotic cohort
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Synthetic Biologics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-TOVX-025104 · Corrections policy